Pediatrix Medical Group Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Pediatrix Medical Group şirketinin kazançları yıllık ortalama -38.7% oranında azalırken, Healthcare sektörünün kazançları yıllık 5.3% oranında artan oldu. Gelirler yıllık ortalama 2.4% oranında artan oldu.
Anahtar bilgiler
-38.7%
Kazanç büyüme oranı
-38.7%
EPS büyüme oranı
| Healthcare Sektör Büyümesi | 8.5% |
| Gelir büyüme oranı | 2.4% |
| Özkaynak getirisi | -34.7% |
| Net Marj | -12.6% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Pediatrix Medical Group, Inc. (NYSE:MD) Shares Fly 27% But Investors Aren't Buying For Growth
Nov 06
Here's Why Pediatrix Medical Group (NYSE:MD) Has A Meaningful Debt Burden
Oct 19We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)
Sep 28Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified
Aug 07Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger
May 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking
Mar 29Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors
Dec 25Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?
Oct 13Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold
Aug 08At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?
Jul 03The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing
Jun 08Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?
Feb 20Pediatrix Medical Group Q4 2022 Earnings Preview
Feb 16Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold
Dec 22Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing
Dec 20Pediatrix appoints James Swift as chief executive officer
Dec 15Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Nov 05Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M
Nov 03Pediatrix: These 5 Graphs Suggest It's A Buy
Sep 29Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return
Aug 29Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Jul 27Pediatrix: Seeking 46% Return Objective As Speculative Buy
Jul 14MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jun 24MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet
May 25Return Trends At MEDNAX (NYSE:MD) Aren't Appealing
Apr 20MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 08MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly
Feb 15Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital
Jan 19Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Pediatrix Medical Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 2,007 | -254 | 228 | 0 |
| 30 Jun 24 | 2,002 | -252 | 227 | 0 |
| 31 Mar 24 | 1,999 | -71 | 229 | 0 |
| 31 Dec 23 | 1,995 | -60 | 228 | 0 |
| 30 Sep 23 | 2,012 | 88 | 226 | 0 |
| 30 Jun 23 | 1,995 | 95 | 226 | 0 |
| 31 Mar 23 | 1,981 | 98 | 229 | 0 |
| 31 Dec 22 | 1,972 | 63 | 231 | 0 |
| 30 Sep 22 | 1,957 | 79 | 239 | 0 |
| 30 Jun 22 | 1,960 | 82 | 248 | 0 |
| 31 Mar 22 | 1,947 | 82 | 258 | 0 |
| 31 Dec 21 | 1,911 | 108 | 263 | 0 |
| 30 Sep 21 | 1,829 | 72 | 259 | 0 |
| 30 Jun 21 | 1,797 | 38 | 259 | 0 |
| 31 Mar 21 | 1,739 | 14 | 248 | 0 |
| 31 Dec 20 | 1,734 | -10 | 249 | 0 |
| 30 Sep 20 | 1,776 | -4 | 253 | 0 |
| 30 Jun 20 | 1,770 | 11 | 250 | 0 |
| 31 Mar 20 | 1,678 | 1 | 230 | 0 |
| 31 Dec 19 | 1,780 | 42 | 245 | 0 |
| 30 Sep 19 | 2,210 | 94 | 291 | 0 |
| 30 Jun 19 | 2,603 | 143 | 323 | 0 |
| 31 Mar 19 | 3,145 | 221 | 384 | 0 |
| 31 Dec 18 | 1,723 | 122 | 232 | 0 |
| 30 Sep 18 | 3,477 | 333 | 450 | 0 |
| 30 Jun 18 | 3,497 | 337 | 456 | 0 |
| 31 Mar 18 | 3,475 | 326 | 458 | 0 |
| 31 Dec 17 | 3,253 | 305 | 386 | 0 |
| 30 Sep 17 | 3,378 | 262 | 443 | 0 |
| 30 Jun 17 | 3,337 | 293 | 435 | 0 |
| 31 Mar 17 | 3,266 | 312 | 424 | 0 |
| 31 Dec 16 | 3,183 | 325 | 411 | 0 |
| 30 Sep 16 | 3,094 | 340 | 393 | 0 |
| 30 Jun 16 | 2,988 | 334 | 379 | 0 |
| 31 Mar 16 | 2,893 | 336 | 360 | 0 |
| 31 Dec 15 | 2,780 | 336 | 338 | 0 |
| 30 Sep 15 | 2,689 | 332 | 316 | 0 |
| 30 Jun 15 | 2,593 | 327 | 296 | 0 |
| 31 Mar 15 | 2,512 | 322 | 285 | 0 |
| 31 Dec 14 | 2,439 | 317 | 275 | 0 |
| 30 Sep 14 | 2,356 | 308 | 262 | 0 |
| 30 Jun 14 | 2,284 | 299 | 256 | 0 |
| 31 Mar 14 | 2,218 | 289 | 250 | 0 |
| 31 Dec 13 | 2,154 | 281 | 245 | 0 |
Kaliteli Kazançlar: MD şu anda kârlı değil.
Büyüyen Kar Marjı: MD şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: MD kârlı değildir ve zararlar son 5 yılda yılda 38.7% oranında artmıştır.
Büyüme Hızlandırma: MD 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: MD kârlı olmadığından, geçmiş yıl kazanç büyümesinin Healthcare sektörüyle ( 9.1% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: MD hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -34.65% ) sahiptir.